Kaverina N V, Lyskovzev V V, Grigoreva J K, Senova Z P, Sulakvelidze M T, Grizenko A N
Pharmazie. 1985 Dec;40(12):845-7.
The intense antifibrillatory and antiarrhythmic actions of GS 015, a derivative of the novel structure series of the 5-(beta-aminoacyl)-3-carbalkoxyamino-iminodibenzyles, are demonstrated on models of myocardial ischaemia: antifibrillatory action on the acute coronary occlusion in the conscious rat (1.0 mg/kg i.v.) and antiarrhythmic action on the two-step coronary ligature in the conscious dog according to Harris (2.0 mg/kg i.v. and 5.0 mg/kg orally). On the strength of the present results it is discussed that GS 015 is first of all suitable for influencing "early arrhythmias" with re-entry mechanism and only in the second line for taking an influence on "late arrhythmias" which arise from the occurrence of ectopic focuses. The substance seems suitable for preventing terminal arrhythmias in patients with ischaemic heart disease as well as for treating arrhythmias in the acute stage of myocardial infarction.
新型结构系列5-(β-氨基酰基)-3-烷氧羰基氨基-亚氨基二苄基衍生物GS 015的强烈抗纤颤和抗心律失常作用在心肌缺血模型上得到证实:对清醒大鼠急性冠状动脉闭塞具有抗纤颤作用(静脉注射1.0mg/kg),对清醒犬根据哈里斯法进行的两步冠状动脉结扎具有抗心律失常作用(静脉注射2.0mg/kg和口服5.0mg/kg)。根据目前的结果讨论认为,GS 015首先适用于影响具有折返机制的“早期心律失常”,其次才适用于影响由异位灶出现引起的“晚期心律失常”。该物质似乎适用于预防缺血性心脏病患者的终末期心律失常以及治疗心肌梗死急性期的心律失常。